Ordin nr. 1301/500/2008 din 11 iulie 2008 Partea a ii-a

Nu se va prescrie în regim compensat pentru tratamentul litiazei biliare.
Se aplică tuturor denumirilor comerciale, formelor farmaceutice şi concentraţiilor corespunzătoare DCI-ului.
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

A05AA02 ACIDUM CAPS. 250 mg

URSODEOXYCHOLICUM

URSOFALK(R) 250 mg DR. FALK PHARMA GMBH

URSOSAN 250 mg PRO. MED. CS PRAHA AS

________________________________________________________________________________

______________________________________________________________________________

| 938 |B01AB05| ENOXAPARINUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

B01AB05 ENOXAPARINUM SOL. INJ. 2000 ui

anti-Xa/0.2 ml

CLEXANE 2000 ui 2000 ui anti-Xa/0.2 ml LAB. AVENTIS

anti-Xa/0.2 ml

B01AB05 ENOXAPARINUM SOL. INJ. 4000 ui

anti-Xa/0,4 ml

CLEXANE 4000 ui 4000 ui anti-Xa/0,4 ml LAB. AVENTIS

anti-Xa/0.4 ml
B01AB05 ENOXAPARINUM SOL. INJ. 6000 ui

anti-Xa/0.6 ml

CLEXANE 6000 ui 6000 ui anti-Xa/0.6 ml LAB. AVENTIS

anti-Xa/0.6 ml

B01AB05 ENOXAPARINUM SOL. INJ. 8000 ui

anti-Xa/0.8 ml

CLEXANE 8000 ui 8000 ui anti-Xa/0.8 ml LAB. AVENTIS

anti-Xa/0.8 ml

B01AB05 ENOXAPARINUM SOL. INJ. 2000 ui

anti-Xa/0.2 ml

CLEXANE 2000 ui 2000 ui anti-Xa/0.2 ml LAB. AVENTIS

anti-Xa/0.2 ml

B01AB05 ENOXAPARINUM SOL. INJ. 4000 ui

anti-Xa/0,4 ml

CLEXANE 4000 ui 4000 ui anti-Xa/0,4 ml LAB. AVENTIS

anti-Xa/0.4 ml

B01AB05 ENOXAPARINUM SOL. INJ. 6000 ui

anti-Xa/0.6 ml

CLEXANE 6000 ui 6000 ui anti-Xa/0.6 ml LAB. AVENTIS

anti-Xa/0.6 ml

________________________________________________________________________________
______________________________________________________________________________

| 939 |B01AB08| REVIPARINUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

B01AB08 REVIPARINUM SOL. INJ. 1432 ui/0.25 ml

CLIVARIN(R) 1432 UI/0.25 ml 1432 ui/0.25 ml ABBOTT GMBH & CO. KG
B01AB08 REVIPARINUM SOL. INJ. 3436 ui/0.6 ml

CLIVARIN(R) 3436 UI/0,6 ml 3436 ui/0.6 ml ABBOTT GMBH & CO. KG

________________________________________________________________________________
______________________________________________________________________________

| 940 |B01AC11| ILOPROSTUM** | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

B01AC11 ILOPROSTUM CONC. PT. SOL. PERF. 20 µg/ml

ILOMEDIN(R) 20 20 µg/ml SCHERING AG

________________________________________________________________________________

______________________________________________________________________________

| 941 |B01AD02| ALTEPLASUM** | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

B01AD02 ALTEPLASUM LIOF. + SOLV. PT. SOL. 50 mg

INJ.

ACTILYSE 50 mg BOEHRINGER INGELHEIM INT.

GMBH

________________________________________________________________________________

______________________________________________________________________________

| 944 |C03EB01| COMBINAŢII (SPIRONOLACTONUM + FUROSEMIDUM) | |

|_______|_______|____________________________________________|_________________|
Electroliţii serici trebuie să fie verificaţi periodic.
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

C03EB01 COMBINAŢII CAPS.

(SPIRONOLACTONUM +

FUROSEMIDUM)

DIUREX 50 TERAPIA SA

________________________________________________________________________________

______________________________________________________________________________

| 945 |H01BA02| DESMOPRESSINUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

H01BA02 DESMOPRESSINUM

MINIRIN 0,2 mg 0.2 mg FERRING AB
H01BA02 DESMOPRESSINUM COMPR. 0.2 mg

MINIRIN 0,2 mg 0.2 mg FERRING AB

________________________________________________________________________________
______________________________________________________________________________

| 946 |J01CR05| PIPERACILLINUM + TAZOBACTAMUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J01CR05 PIPERACILLINUM + LIOF. PT. SOL. INJ.

TAZOBACTAMUM

TAZOCIN 2,25 WYETH LEDERLE PHARMA GMBH

TAZOCIN 4,5 WYETH LEDERLE PHARMA GMBH

________________________________________________________________________________

______________________________________________________________________________

| 947 |J01XX08| LINEZOLIDUM | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J01XX08 LINEZOLIDUM GRAN. PT. SUSP. ORALA 100 mg/5 ml

ZYVOXID(R) 100 mg/5 ml PFIZER EUROPE MA EEIG
J01XX08 LINEZOLIDUM SOL. PERF. 2 mg/ml

ZYVOXID(R) 2 mg/ml PFIZER EUROPE MA EEIG

J01XX08 LINEZOLIDUM COMPR. FILM. 600 mg

ZYVOXID(R) 600 mg PFIZER EUROPE MA EEIG

________________________________________________________________________________
______________________________________________________________________________

| 948 |J02AC03| VORICONAZOLUM** | Protocol: J012B |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J02AC03 VORICONAZOLUM COMPR. FILM. 200 mg

VFEND 200 mg 200 mg PFIZER LTD.
J02AC03 VORICONAZOLUM PULB. PT. SOL. PERF. 200 mg

VFEND 200 mg 200 mg PFIZER LTD.

J02AC03 VORICONAZOLUM PULB. PT. SUSP. ORALA 40 mg/ml

VFEND 40 mg/ml 40 mg/ml PFIZER LTD.

J02AC03 VORICONAZOLUM COMPR. FILM. 50 mg

VFEND 50 mg 50 mg PFIZER LTD.

________________________________________________________________________________
______________________________________________________________________________

| 949 |J02AX04| CASPOFUNGINUM** | Protocol: J010D |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J02AX04 CASPOFUNGINUM PULB. PT. CONC. PT. 50 mg

SOL. PERF.

CANCIDAS 50 mg 50 mg MERCK SHARP & DOHME LTD

J02AX04 CASPOFUNGINUM PULB. PT. CONC. PT. 70 mg

SOL. PERF.

CANCIDAS 70 mg 70 mg MERCK SHARP & DOHME LTD

________________________________________________________________________________

______________________________________________________________________________

| 951 |J05AB14| VALGANCICLOVIRUM** | |

|_______|_______|____________________________________________|_________________|
Prescriere limitată: Tratamentul de iniţiere şi menţinere pentru retinita cu citomegalovirus (CMV) la pacienţi imunocompromişi.
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

J05AB14 VALGANCICLOVIRUM COMPR. FILM. 450 mg

VALCYTE(R) 450 mg 450 mg ROCHE ROMANIA SRL

________________________________________________________________________________

______________________________________________________________________________

| 953 |L03AA02| FILGRASTIMUM (G-CSF) | |

|_______|_______|____________________________________________|_________________|
________________________________________________________________________________

DCI/DENUMIRE COMERCIALĂ FORMA FARM.

__________________________________________________

CONCENTRAŢIE FIRMA

________________________________________________________________________________

L03AA02 FILGRASTIMUM (G-CSF) SOL. INJ. 30 MU/0.5 ml

NEUPOGEN(R) 30 MU/0.5 ml AMGEN EUROPE B.V.
L03AA02 FILGRASTIMUM (G-CSF) SOL. INJ. 48 MU/0.5 ml

NEUPOGEN(R) 48 MU/0.5 ml AMGEN EUROPE B.V.

________________________________________________________________________________
______________________________________________________________________________

| 954 |L04AA01| CICLOSPORINUM | |

|_______|_______|____________________________________________|_________________|
Prescriere limitată: Managementul rejectului de grefă la pacienţii supuşi procedurii de transplant.

Monitorizarea atentă a pacienţilor este obligatorie.